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LETTER TO THE EDITOR
The TAF1/DYT3 Multiple Transcript System
in X-Linked Dystonia-Parkinsonism
To the Editor: The X-linked dystonia-parkinsonism syn-
drome (XDP or DYT3 [MIM #314250]) is a severe adult-
onset movement disorder that originated by founder ef-
fect in the Philippine island of Panay.1 The disease gene
was identiﬁed in 2003 and was described as a “multiple
transcript system.” It is composed of several of the 38
known TAF1 (TATA-box binding protein–associated factor
1) exons and an additional 5 of the then-unknown exons
that lie 3′ of TAF1 exon 38.2 The latter ﬁve exons can either
be spliced to known TAF1 exons (variants 1 and 2) or be
transcribed separately (variants 3 and 4). Five disease-spe-
ciﬁc single-nucleotide changes (DSCs) and a small deletion
were detected within this transcript system. One of the
DSCs (DSC3) is located in a transcribed exon. These ﬁnd-
ings have now been conﬁrmed by Makino and coworkers
in the March issue of the Journal.3 Whereas, in the original
study, the DYT3 critical region was sequenced by PCR in
a patient, Makino et al.3 resequenced this region in BAC
clones constructed from a patient’s DNA. The resequenc-
ing conﬁrmed the DSCs described elsewhere2 and detected
a previously unrecognized retrotransposon (SVA [SINE,
VNTR, and Alu] element) in intron 32 of TAF1 in close
proximity to DSC10. Makino et al.3 also conﬁrmed the
various splice variants of TAF1 that were found earlier.2
Furthermore, the study by Makino et al.3 validates our use
of several DSCs in the routine molecular genetic diagnosis
of XDP.4
It is currently not known whether or to what extent the
DSCs in TAF1/DYT3 are involved in the disease process.
Makino et al.3 implicate the SVA retrotransposon in intron
32 of TAF1 in the pathology of XDP. They present several
ﬁndings supporting an important role for SVA in XDP. In
particular, they provide evidence that the SVA affects ex-
pression of a transcript splice variant described elsewhere2
that includes exon 34′ of TAF1. However, the data are not
entirely convincing.
1. The article byMakino et al.3 implies that there is only
one splice variant of TAF1 that includes exon 34′. This is
not accurate. There are other splice variants of TAF1 that
also include exon 34′—for example, splice variants in-
cluding exons 34′ and 32′ and splice variants including
exons 34′, 3, and 4.2
2. Figure 5a in the work of Makino et al.3 shows dra-
matic reduction of expression of an exon 34′–containing
transcript but also demonstrates reduced expression of the
common form of TAF1 in a patient’s caudate nucleus. Al-
though antibodies were directed against TAF1 polypep-
tides (and not speciﬁcally against the exon 34′ isoform),
their ﬁgure 5f implies complete absence of TAF1 in the
patient’s caudate. This cannot be explained by gliosis
alone, since calcineurin antibodies deﬁnitely identiﬁed
neurons in the patient’s caudate (see their ﬁgure 5f).
3. Although hypermethylation was shown at CpG sites
of SVA, a correlation between this epigenetic modiﬁcation
and the postulated speciﬁcally reduced expression of the
exon 34′ transcript was not shown.
4. When postmortem brain is used for the quantitative
ascertainment of gene expression, a high degree of vari-
ation has to be kept in mind. Apart from biological rea-
sons, different postmortem times, storage conditions, etc.
account for this variation. This might explain why tran-
script variant 34′ of TAF1 is speciﬁcally reduced in some
experiments but the common form of TAF1 is also affected
in others (their ﬁg. 5a and 5f).
5. Makino et al.3(p402) indicate that the decrease in ex-
pression of the exon 34′ transcript is “the cause rather than
the result of neuronal loss in the caudate nucleus….” This
argument is not entirely convincing, since this transcript
is also reduced in cortex and nucleus accumbens that do
not show major neuronal loss. Makino et al.3 do not pro-
vide evidence of neuronal subtype-speciﬁc expression and
function of the exon 34′ transcript that might explain the
discrepancy.
Obviously, the molecular pathological mechanism in
XDP remains unknown. The involvement of one or several
of the described DSCs, either alone or in concert with the
SVA retrotransposon, certainly cannot be ruled out. Here,
a function of DSC3 is intriguing, since it is located in an
exon that can be part of all major splice variants of the
TAF1/DYT3 transcript system. However, intronic SNPs can
also affect gene expression, as was recently shown with
the SORL1 susceptibility gene for late-onset Alzheimer
disease.5
Several other aspects of the article need further clariﬁ-
cation. In ﬁgure 3, patients are shown carrying the “dis-
ease-speciﬁc” 6.1-kb SVA fragment, but other patients (right
panel of ﬁg. 3) show the “wild-type” fragment. Can the
SVA fragment occur in healthy persons as well, or has a
sample mix-up occurred? Makino et al.3 claim that exon
2, described elsewhere2 (3′ of TAF1 exon 38), is derived
from ING2. This is not the case, since the ING2 pseudo-
gene overlaps with exon 2 on the opposite strand. Exon
38 of TAF1 is skipped when further 3′ exons are used in
a transcript. This was shown in cDNAs isolated from a
brain cDNA bank and in RT-PCR experiments.2 Makino et
al.,3 however, report the presence of this exon in these
alternative transcripts. Provided that this is no RT-PCR
artifact, this does not disprove previous ﬁndings of the
absence of exon 38 in some splice variants that include
additional 3′ exons.
In conclusion, many issues remain unresolved as to
both the normal function of TAF1 variants in various tis-
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sues and the role of disease-speciﬁc changes in the TAF1/
DYT3 multiple transcript system in patients with XDP.
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